1. Home
  2. PLSE vs HROW Comparison

PLSE vs HROW Comparison

Compare PLSE & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$44.54

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$40.03

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
HROW
Founded
2014
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
PLSE
HROW
Price
$44.54
$40.03
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$22.00
$69.86
AVG Volume (30 Days)
419.8K
583.5K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
71.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
$31.62
Revenue Next Year
$287.54
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$28.54
52 Week High
$46.97
$54.98

Technical Indicators

Market Signals
Indicator
PLSE
HROW
Relative Strength Index (RSI) 75.57 48.17
Support Level $24.27 $37.03
Resistance Level N/A $41.82
Average True Range (ATR) 3.09 1.94
MACD 0.71 -0.06
Stochastic Oscillator 83.20 52.97

Price Performance

Historical Comparison
PLSE
HROW

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: